Teladoc Health Reviews Liraglutide
Part of the broader chronic-care formulary and usable as a configured step-therapy rung, though it is not the default pathway.
Sold as Saxenda, Victoza · Reviewed September 19, 2026
What “Adjunct” means here
Available and used, but not the centre of the protocol — typically alongside or after another agent.
The pairing
How Teladoc Health handles Liraglutide
These are the vendor-specific mechanics that determine what this molecule actually costs you and whether members stay on it long enough to benefit.
- Access status
- Adjunct
- Gating
- Employer-configured.
- Prescribes directly
- Yes
- Step therapy
- Yes
- Prior authorization
- Yes
- Titration protocol
- Configurable to employer policy; defaults to conservative escalation
- Off-ramp
- Chronic-care management continues after weight targets are met
- Care team
- Physicians, Nurse practitioners, Certified diabetes educators, Coaches
Ask Teladoc Health this
If we configure liraglutide as a mandatory trial before the weekly agents, how is the failure criterion defined and who adjudicates it?
Watch out
Bundled pricing obscures what you actually pay for weight management. Demand the standalone line item before comparing.
The molecule
Liraglutide in one page
The first-generation daily GLP-1. Lower efficacy than the weekly agents, but generic entry has made it the cheapest genuine GLP-1 option and a credible step-therapy rung.
Clinical profile
- Drug class
- GLP-1 receptor agonist
- Brand names
- Saxenda — Chronic weight managementVictoza — Type 2 diabetes
- Mechanism
- Single GLP-1 receptor agonist with a shorter half-life than the weekly agents, requiring daily administration to maintain effect.
- Administration
- Once-daily subcutaneous injection. Daily dosing is the main adherence disadvantage versus weekly agents.
- Titration
- Weekly dose escalation over roughly a month to the maintenance dose — a substantially shorter ladder than the weekly agents.
- Typical result
- Average body-weight reduction in the high single digits as a percentage — roughly half what the newer agents produce, though achieved faster and at a fraction of the cost.
- Generic available
- Yes
Known side effects
- Gastrointestinal effects similar in kind to the weekly agents
- Injection-site reactions somewhat more common given daily administration
- Class boxed warning regarding thyroid C-cell tumors observed in rodents
What benefits teams need to know
This is your step-therapy rung
Generic availability makes liraglutide the only GLP-1 that can sit meaningfully below the weekly agents on cost. A vendor that will genuinely trial it before escalating has a real cost-control mechanism; one that lists it and never uses it does not.
Adherence is the honest tradeoff
Daily injection produces worse persistence than weekly dosing. A step-therapy protocol built on this molecule needs to distinguish members who failed on efficacy from members who failed on adherence, because they warrant different escalation decisions.
Alternatives
Other vendors and Liraglutide
Same molecule, materially different access rules. The status column is where the cost difference lives.
| Vendor | Access | Score | PMPM |
|---|---|---|---|
| Omada Health Coaching companion | Companion support | 8.4 | $32–$58 |
| Form Health Full-service clinical | First-line | 8.0 | $58–$105 |
| 9amHealth Metabolic specialist | Adjunct | 7.3 | $34–$72 |
| Calibrate Full-service clinical | Adjunct | 7.2 | $65–$110 |
| Transcarent Navigation & orchestration | Orchestrated | 7.1 | $12–$32 |
| WeightWatchers Clinic Consumer-brand clinical | Adjunct | 6.9 | $30–$68 |
Same vendor
Teladoc Health across the formulary
How this vendor positions each molecule tells you more about its cost discipline than any single review does.
Available first-line, but the decisive feature is that eligibility and step-therapy rules are employer-configurable. Your policy governs access here, not Teladoc's clinical defaults — which is the strongest argument for buying it.
Same configurable posture as semaglutide. For a large employer running multiple point solutions, uniform policy enforcement across both molecules is worth more than any individual clinical feature.
Core to the chronic-care model, which predates the weight-management line and covers diabetes management at national scale.